Igenica Biotherapeutics
Total Raised
$85.73MInvestors Count
5Deal Terms
5Funding, Valuation & Revenue
8 Fundings
Igenica Biotherapeutics has raised $85.73M over 8 rounds.
Igenica Biotherapeutics's latest funding round was a Asset Sale for on May 24, 2017.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
5/24/2017 | Asset Sale | 1 | ||||
10/14/2015 | Series F | |||||
6/9/2015 | Series E | |||||
1/26/2015 | Series D | |||||
1/28/2014 | Series C - II |
Date | 5/24/2017 | 10/14/2015 | 6/9/2015 | 1/26/2015 | 1/28/2014 |
|---|---|---|---|---|---|
Round | Asset Sale | Series F | Series E | Series D | Series C - II |
Amount | |||||
Investors | |||||
Valuation | |||||
Revenue | |||||
Sources | 1 |
Igenica Biotherapeutics Deal Terms
5 Deal Terms
Igenica Biotherapeutics's deal structure is available for 5 funding rounds, including their Series D from January 26, 2015.
Round | Series D | Series C - II | Series C | Series B | Series A |
|---|---|---|---|---|---|
Funding Date | |||||
Pre-Money Valuation | |||||
Post-Money Valuation | |||||
Amount Raised | |||||
Shares Authorized | |||||
Issuance Price | |||||
Dividend Rate | |||||
Liquidation Preferences | |||||
Liquidation Price | |||||
Participation | |||||
Conversion Price | |||||
Anti Dilution | |||||
General Voting | |||||
Board Voting | |||||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series D | |||||||||||||||
Series C - II | |||||||||||||||
Series C | |||||||||||||||
Series B | |||||||||||||||
Series A |
Igenica Biotherapeutics Investors
5 Investors
Igenica Biotherapeutics has 5 investors. Pierre Fabre invested in Igenica Biotherapeutics's Asset Sale funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
5/24/2017 | 5/24/2017 | 1 Asset Sale | Corporation | France | ||
Venture Capital | California | |||||
Venture Capital | California | |||||
Venture Capital | Massachusetts | |||||
Venture Capital | New York |
First funding | 5/24/2017 | ||||
|---|---|---|---|---|---|
Last Funding | 5/24/2017 | ||||
Investor | |||||
Rounds | 1 Asset Sale | ||||
Board Seats | |||||
Type | Corporation | Venture Capital | Venture Capital | Venture Capital | Venture Capital |
Location | France | California | California | Massachusetts | New York |
Compare Igenica Biotherapeutics to Competitors
Neomics is a genomic analysis center that provides services to interpret genomic sequences for guiding diagnosis and treatment, utilizing sequencing technologies. Neomics serves the healthcare sector, including clinicians and researchers. It is based in Gyeonggi-do, South Korea.
NanoMedica aims to become engaged in design,development and manufacture of dual-action therapeutics for the treatment of human cancer.
Eximias is developing late stage cancer therapeutics. Eximias is now a wholly-owned subsidiary of YM named YM BioSciences USA
Falcon Genomics, Inc. is focused on functional genomics as a tool for cancer diagnostics and therapeutics.
Pro-Cure Therapeutics provides tools for scientific research with a focus on behavioral neuroscience and lab equipment. The company offers products including automated mazes and behavior analysis software for research in neuroscience and behavioral psychology. Pro-Cure Therapeutics supports various sectors within the scientific community, providing tools for behavioral experiments and virtual reality science. It was founded in 2001 and is based in United Kingdom.
Signase is a cancer therapeutics company developing small molecule inhibitors of a critical cell replication pathway to inhibit tumor growth. Signase was spun out of the M. D. Anderson Cancer Center.
Loading...